Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity

The senior-author tumour-microenvironment programme statement on how interstitial and lymphatic flow shape immune escape in solid cancers. Melody A. Swartz (then at EPFL Lausanne, since 2014 at the University of Chicago Pritzker School of Molecular Engineering) is the principal architect of the modern tumour-lymphatic-flow field; Amanda Lund was a postdoctoral fellow with Swartz at the time and now runs her own group at OHSU on tumour immunology and lymphatic biology. The collaboration represents the Swartz lab at the moment its programme had consolidated into a recognisable school.

Published in Nature Reviews Cancer in March 2012, the piece is a synthesising review that joins the cancer-microenvironment and mechanobiology literatures with the tumour-immunology literature. The argument has two halves. First, that tumours engage the lymphatic system actively rather than passively: the tumour- draining lymph node is partly an immune-privileged site, recruiting tolerogenic dendritic cells and regulatory T cells in ways that suppress anti-tumour immunity. Second, that the increased lymph flow at the tumour invasive edge mechanically stiffens the stromal matrix and alters stromal cell behaviour in metastasis-favouring ways. The synthesis ties interstitial-flow mechanics to immune escape — a connection neither field had made in this form before.

The piece sits as the bridge between Wiig and Swartz 2012 (the same year, the basic-physiology side) and the cancer literature, and as the foundational citation for the post-2012 tumour-lymphatic immunology programme. The Munson clinical review cites it heavily; the post-2012 work on flow-induced immune escape and on lymphatic-targeted immunotherapy runs through Swartz's lab and its descendants.

The stake is scientific and clinical-translational. Swartz has built a substantial laboratory programme on lymphatic-targeted immunotherapy at the Pritzker School, with several startup ventures spinning out. The clinical implications — that modulating lymphatic flow could enhance immune response to tumours, that lymphatic-targeted vaccine delivery could improve outcomes — have generated funding interest from cancer-immunotherapy companies. The review's empirical synthesis is careful, and its theoretical bridge between mechanobiology and immunity is the field's working frame.